129 related articles for article (PubMed ID: 31668826)
1. Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma.
Thomas TS; Luo S; Reagan PM; Keller JW; Sanfilippo KM; Carson KR
J Geriatr Oncol; 2020 Jan; 11(1):69-74. PubMed ID: 31668826
[TBL] [Abstract][Full Text] [Related]
2. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
Taparra K; Liu H; Polley MY; Ristow K; Habermann TM; Ansell SM
Leuk Lymphoma; 2020 Feb; 61(2):298-308. PubMed ID: 31517559
[TBL] [Abstract][Full Text] [Related]
3. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
Sun HL; Atenafu EG; Tsang R; Kukreti V; Marras TK; Crump M; Kuruvilla J
Leuk Lymphoma; 2017 Nov; 58(11):2607-2614. PubMed ID: 28504035
[TBL] [Abstract][Full Text] [Related]
4. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
5. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?
Abou Yehia Z; Mikhaeel GN; Smith G; Pinnix CC; Milgrom SA; Tang C; Jiang W; Fanale MA; Oki Y; Shank JH; Horace T; Reddy J; Akhtari M; Gunther JR; Suki T; Allen PK; Turner S; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):951-958. PubMed ID: 27742539
[TBL] [Abstract][Full Text] [Related]
6. The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor
Andersen MD; Kamper P; d'Amore A; Clausen M; Bentzen H; d'Amore F
Leuk Lymphoma; 2019 Apr; 60(4):927-933. PubMed ID: 30277120
[TBL] [Abstract][Full Text] [Related]
7. Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.
Al-Jizani WA; Al-Mansour MM; Al-Fayea TM; Shafi RU; Kazkaz GA; Bayer AM; Al-Foheidi ME; Ibrahim EM
Future Oncol; 2015; 11(15):2149-57. PubMed ID: 26235180
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
[TBL] [Abstract][Full Text] [Related]
9. Bleomycin induced pulmonary toxicity in patients with germ cell tumours.
Usman M; Faruqui ZS; ud Din N; Zahid KF
J Ayub Med Coll Abbottabad; 2010; 22(3):35-7. PubMed ID: 22338413
[TBL] [Abstract][Full Text] [Related]
10. Diffusion Lung Capacity Changes In Hodgkin Lymphoma Patients Before And After Abvd Chemotherapy.
Abdullah M; Alam S; Zafar W; Majid A
J Ayub Med Coll Abbottabad; 2016; 28(2):289-292. PubMed ID: 28718544
[TBL] [Abstract][Full Text] [Related]
11. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
Böll B; Goergen H; Behringer K; Bröckelmann PJ; Hitz F; Kerkhoff A; Greil R; von Tresckow B; Eichenauer DA; Bürkle C; Borchmann S; Fuchs M; Diehl V; Engert A; Borchmann P
Blood; 2016 May; 127(18):2189-92. PubMed ID: 26834240
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
13. The role of atopy in the pathogenesis of bleomycin pulmonary toxicity.
Ozyigit LP; Aktas EC; Senbas ZA; Ozturk AB; Ozturk E; Ergonul MO; Tabak L; Ferhanoglu B; Cetiner M; Deniz G
Respir Med; 2019 Aug; 155():1-5. PubMed ID: 31255902
[TBL] [Abstract][Full Text] [Related]
14. Bleomycin in Hodgkin's Lymphoma - A Boon or a Bane? - A Retrospective Study of Bleomycin Pulmonary Toxicity in Hodgkin's Lymphoma.
Udupa CBK; Koteshwar P; Udupa KS
Indian J Palliat Care; 2019; 25(4):523-526. PubMed ID: 31673206
[TBL] [Abstract][Full Text] [Related]
15. The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity - A systematic review and meta-analysis.
Mahdi Seyedzadeh Sani S; Sahranavard M; Jannati Yazdanabad M; Seddigh Shamsi M; Elyasi S; Hooshang Mohammadpour A; Sathyapalan T; Arasteh O; Ghavami V; Sahebkar A
Int Immunopharmacol; 2022 Nov; 112():109227. PubMed ID: 36099787
[TBL] [Abstract][Full Text] [Related]
16. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.
O'Sullivan JM; Huddart RA; Norman AR; Nicholls J; Dearnaley DP; Horwich A
Ann Oncol; 2003 Jan; 14(1):91-6. PubMed ID: 12488299
[TBL] [Abstract][Full Text] [Related]
17. Risk of pulmonary toxicity of bleomycin and filgrastim.
Laprise-Lachance M; Lemieux P; Grégoire JP
J Oncol Pharm Pract; 2019 Oct; 25(7):1638-1644. PubMed ID: 30319063
[TBL] [Abstract][Full Text] [Related]
18. Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.
Ahmed BM; Al-Zakwani IS
J Oncol Pharm Pract; 2013 Mar; 19(1):3-7. PubMed ID: 22504168
[TBL] [Abstract][Full Text] [Related]
19. Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity.
Jóna Á; Miltényi Z; Ujj Z; Garai I; Szilasi M; Illés Á
Expert Opin Drug Saf; 2014 Oct; 13(10):1291-7. PubMed ID: 25135756
[TBL] [Abstract][Full Text] [Related]
20. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
